BioSpace News Archive

Data from Phase 2 portion of mavrilimumab Phase 2/3 trial in severe COVID-19 pneumonia and hyperinflammation expected in 1H 2021

Potential best-in-class ADAR editing platform capability continues to advance, with validation of proprietary in vivo modeling system and delivery of in vivo alpha-1 antitrypsin deficiency data expected 1H 2021

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to highlight an independent research review (the “Review”) published in the January 5th edition of the European Archives of Psychiatry and Clinical Neuroscience, that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19.

EXUMA Biotech Corp., a clinical-stage biotechnology company discovering and developing chimeric antigen receptor (CAR)-T products and delivery solutions for liquid and solid tumors, announced today that the company has entered into a strategic collaboration with Moffitt Cancer Center to develop EXUMA’s first rapid point-of-care

- 2021 Revenue Guidance of $375 to $395 Million Representing 40%-45% Growth over Expected 2020 Revenue - - 2021 Royalties Projected to Double versus Expected 2020 Royalties - - 2021 EPS Guidance of $1.40 to $1.55 Representing 55%-70% Growth over Expected 2020 EPS -

OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that renowned biologist and winner of The Nobel Prize in Chemistry, Professor Aaron Ciechanover, has joined the company’s scientific advisory board.

The Foundry today announced the successful completion of the first-in-human procedure with the Half Moon Medical transcatheter mitral repair technology (TMVr) at Oregon Health and Science University (OHSU) as part of an FDA-approved early feasibility study.

-- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 -- -- XPOVIO® (selinexor) Unaudited Net Product Sales of between $20.0 Million and $20.5 Million for Fourth Quarter 2020 and between $76.0 Million and $76.5 Million for the Full Year 2020 -- -- Commercial Launch of XPOVIO in Expanded Multiple Myeloma Indication Fully Underway --

Unchained Labs, the life sciences company that’s all about getting researchers the right tool for the job, launched its new mRNA vaccine application on Stunner.

Penumbra, Inc. (the “Company”) ( NYSE: PEN ), a global healthcare company focused on innovative therapies, today announced certain unaudited preliminary revenue results for the fourth quarter and full year 2020 ahead of its participation at the 39 th Annual J.P. Morgan Healthcare Conference on January 11-14, 2021 .